Organization
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
2 abstracts
Abstract
Sintilimab plus axitinib for advanced fumarate hydratase-deficient renal cell carcinoma: A multi-center, open-label, single-arm, phase II study (SAFH).Org: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Department of Radiology, West China Hospital, Sichuan University, Chengdu, China, Department of Urology, Southwest Hospital, Army Medical University, Chongqing, Chengdu, China, The First Affiliated Hospital of Kunming Medical University, Kunming, China,
Abstract
SI-B003 (PD-1/CTLA-4) in patients with advanced solid tumors: A phase I study.Org: Department of Early Drug Development Center, Peking University Cancer Hospital & Institute, Beijing, China, Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China, Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, Henan Cancer Hospital, Zhengzhou, China, Shanghai General Hospital, Shanghai, China,